Online citations, reference lists, and bibliographies.
← Back to Search

Riluzole And Prognostic Factors In Amyotrophic Lateral Sclerosis Long-term And Short-term Survival: A Population-Based Study Of 1149 Cases In Taiwan

C. T. Lee, Y. Chiu, Kai-chen Wang, Chi-shin Hwang, Kuan-Hsiang Lin, I-Ta Lee, Ching-Piao Tsai
Published 2013 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Background Amyotrophic lateral sclerosis (ALS) is a rare disease in Taiwan; thus, estimation of ALS mortality is difficult. We evaluated factors associated with ALS survival in Taiwan. Methods The study enrolled 1149 Taiwanese with a primary diagnosis of ALS during 1999–2008. Follow-up information was available for all patients; mean (SD) duration of follow-up was 2.91 (2.62) years. Medical interventions, including noninvasive positive pressure ventilation (NIPPV), tracheotomy, gastrostomy, and riluzole, were included in time-dependent survival analysis. Results Of the 1149 ALS patients, 438 (38.12%) died during follow-up. Mortality in the first year was 16%, which was 13 times (95% CI 11.1–15.2) the age- and sex-standardized rate of the general population in Taiwan. The average annual crude mortality rate was 13.1% (person-years). Factors significantly associated with increased mortality were male sex, advanced age, rural residence, lower economic status, no tracheotomy, and no riluzole treatment. Significant predictors of long-term versus average survival were younger age at diagnosis, being a dependent or receiving social welfare, and NIPPV support. Significant predictors of short-term versus average survival were older age, being employed, no tracheotomy, and no riluzole use. Conclusions The results support the use of riluzole to improve ALS survival. Patients who received riluzole and underwent tracheotomy had the best survival.
This paper references
Amyotrophic lateral sclerosis in Sweden
F Fang (1991)
10.1016/0022-510X(94)90191-0
El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis
B. Brooks (1994)
Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between
O O’Toole (1995)
10.1212/WNL.47.6_Suppl_4.233S
The pharmacology and mechanism of action of riluzole
A. Doble (1996)
10.1016/S0140-6736(96)91680-3
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
Amyotrophic Lateral SclerosisRiluzole Study Group (1996)
Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.
L. Lacomblez (1996)
Riluzole) may extend survival in amyotrophic lateral sclerosis
(1996)
Riluzole ) may extend survival in amyotrophic lateral sclerosis
Rilutek (1996)
10.1007/s004150050641
Mechanical ventilation in amyotrophic lateral sclerosis: a cross-cultural perspective
G. Borasio (1998)
Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and
O Oapostoole (2004)
10.1201/9781420057225
Statistical Analysis of Medical Data Using SAS
G. Der (2005)
10.2188/jea.15.20
Descriptive Epidemiology of Amyotrophic Lateral Sclerosis in Japan, 1995-2001
K. Okamoto (2005)
10.2188/jea.15.1
Excessive Daytime Sleepiness among the Japanese General Population
Y. Kaneita (2005)
10.1080/14660820510028412a
An epidemiological study of motor neuron disease in Hong Kong
G. C. Fong (2005)
10.1212/01.WNL.0000238978.69141.57
NIPPV: a treatment for ALS whose time has come.
T. Heiman-Patterson (2006)
10.1136/jnnp.2007.117788
Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and 2004
O. O'Toole (2007)
10.1136/jnnp.2007.118018
Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study
S. Zoccolella (2007)
10.1111/j.1468-1331.2006.01575.x
Riluzole and amyotrophic lateral sclerosis survival: a population‐based study in southern Italy
S. Zoccolella (2007)
10.1016/j.jns.2007.10.023
Predictors of long survival in amyotrophic lateral sclerosis: A population-based study
S. Zoccolella (2008)
10.5692/clinicalneurol.48.973
[End of life care for patients with ALS in Japan].
Mieko Ogino (2008)
10.1016/j.jns.2008.04.034
Clinical characteristics and survival pattern of 1153 patients with amyotrophic lateral sclerosis: Experience over 30 years from India
A. Nalini (2008)
10.1016/j.jns.2007.11.011
Survival rate of patients with amyotrophic lateral sclerosis in Wakayama Prefecture, Japan, 1966 to 2005
T. Kihira (2008)
10.1001/archneurol.2009.13
Amyotrophic lateral sclerosis in Sweden, 1991-2005.
F. Fang (2009)
10.1001/archneurol.2009.1
Defining survival as an outcome measure in amyotrophic lateral sclerosis.
P. Gordon (2009)
10.1002/14651858.cd004427.pub2
Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease.
A. Radunović (2009)
10.1111/j.1468-1331.2010.03036.x
Amyotrophic lateral sclerosis: gender differences in the use of mechanical ventilation
E. Tollefsen (2010)
10.1136/jnnp.2009.175984
Tracheostomy in amyotrophic lateral sclerosis: a 10-year population-based study in Italy
A. Chiò (2010)
10.1016/j.genm.2010.11.010
Effects of gender in amyotrophic lateral sclerosis.
P. McCombe (2010)
10.3109/17482960902991773
Use of respiratory function tests to predict survival in amyotrophic lateral sclerosis
F. Baumann (2010)
10.3109/17482968.2010.550302
Survival and clinical features in Hispanic amyotrophic lateral sclerosis patients
H. R. Martinez (2011)
10.1590/S0004-282X2011000700003
Epidemiology of amyotrophic lateral sclerosis patients in a centre in Buenos Aires.
M. Bettini (2011)



This paper is referenced by
10.3389/fneur.2021.633854
Administration of Riluzole Oral Suspension During the Different Stages of Amyotrophic Lateral Sclerosis
M. Povedano Panadés (2021)
10.1080/21678421.2021.1874992
Effect of riluzole on weight in short-term and long-term survivors of amyotrophic lateral sclerosis
Kinjal Thakor (2021)
10.1007/s13691-021-00499-7
Robot-assisted total gastrectomy for gastric cancer in a patient with amyotrophic lateral sclerosis receiving long-term tracheostomy invasive ventilation
M. Nishi (2021)
10.1097/CM9.0000000000001679
Epidemiology and factors predicting survival of amyotrophic lateral sclerosis in a large Chinese cohort
Ming Gao (2021)
10.1007/s00401-021-02333-z
DDX17 is involved in DNA damage repair and modifies FUS toxicity in an RGG-domain dependent manner
Tyler R Fortuna (2021)
10.1007/s00415-021-10508-7
Prognostic models for amyotrophic lateral sclerosis: a systematic review
Lu Xu (2021)
10.1002/mus.26801
Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS
N. Goyal (2020)
10.1503/cmaj.191721
Canadian best practice recommendations for the management of amyotrophic lateral sclerosis
C. Shoesmith (2020)
10.1080/21678421.2020.1771734
Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis
J. Andrews (2020)
10.1111/ene.14647
Non‐invasive and tracheostomy invasive ventilation in amyotrophic lateral sclerosis: Utilization and survival rates in a cohort study over 12 years in Germany
S. Spittel (2020)
10.1080/21678421.2020.1832121
Natural history and clinical features of ALS in Malaysia
N. A. Abdul Aziz (2020)
10.1080/14737175.2020.1785873
What do we know about the variability in survival of patients with amyotrophic lateral sclerosis?
P. Mccombe (2020)
10.1136/jnnp-2019-322213
Prognosis of amyotrophic lateral sclerosis patients undergoing tracheostomy invasive ventilation therapy in Japan
N. Hayashi (2020)
10.5772/intechopen.91921
Introduction to Novel Motor Neuron Disease
Humberto Foyaca Sibat (2020)
10.1503/cmaj.191721-f
Recommandations canadiennes pour les pratiques optimales de prise en charge de la sclérose latérale amyotrophique
Christen Shoesmith (2020)
10.1371/journal.pone.0220246
Retrospective longitudinal study of ALS in Cyprus: Clinical characteristics, management and survival
C. Demetriou (2019)
10.1016/j.jocn.2019.08.030
Early onset but long survival and other prognostic factors in Chinese sporadic amyotrophic lateral sclerosis
T. Liu (2019)
10.1080/24745332.2018.1559644
Home mechanical ventilation for patients with Amyotrophic Lateral Sclerosis: A Canadian Thoracic Society clinical practice guideline
K. Rimmer (2019)
10.1007/978-3-030-31206-0_14
Targeting Purinergic Signaling and Cell Therapy in Cardiovascular and Neurodegenerative Diseases.
Roberta Andrejew (2019)
10.15252/embj.2018101112
RNA toxicity in non‐coding repeat expansion disorders
Bart Swinnen (2019)
10.1159/000499485
Estimating Amyotrophic Lateral Sclerosis and Motor Neuron Disease Prevalence in Portugal Using a Pharmaco-Epidemiological Approach and a Bayesian Multiparameter Evidence Synthesis Model
B. Conde (2019)
10.1007/978-3-030-31206-0
Stem Cells: Therapeutic Applications
M. Ratajczak (2019)
10.1038/s41467-019-13383-z
Muscleblind acts as a modifier of FUS toxicity by modulating stress granule dynamics and SMN localization
Ian Casci (2019)
10.1007/s00415-019-09652-y
Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis
Lu Xu (2019)
10.1186/s40035-018-0142-8
Better survival in female SOD1-mutant patients with ALS: a study of SOD1-related natural history
L. Tang (2018)
10.1016/j.brainres.2018.02.035
The epidemiology and genetics of Amyotrophic lateral sclerosis in China
Xiao-lu Liu (2018)
10.14336/AD.2017.1016
Prognostic Nomogram Associated with Longer Survival in Amyotrophic Lateral Sclerosis Patients
Qian-qian Wei (2018)
10.3389/fneur.2018.00442
Clinical Staging of Amyotrophic Lateral Sclerosis in Chinese Patients
Xueping Chen (2018)
Suspensión del soporte respiratorio en enfermos con esclerosis lateral amiotrófica
A. Silberberg (2018)
10.1007/s00415-018-8778-y
Riluzole and other prognostic factors in ALS: a population-based registry study in Italy
J. Mandrioli (2018)
10.1016/j.clinph.2017.10.037
Detection radius of EMG for fasciculations: Empiric study combining ultrasonography and electromyography
M. Regensburger (2018)
10.2147/DNND.S135748
Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis
M. Hinchcliffe (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar